idarucizumab sold brand name praxbind monoclonal antibody used reversal agent idarucizumab developed boehringer ingelheim one study sponsored manufacturer found idarucizumab effectively reversed anticoagulation caused dabigatran within approved medical use united states european union idarucizumab international nonproprietary name description updated idarucizumab united states adopted name monoclonal article stub help wikipedia expanding httpsenwikipediaorgwikiidarucizumab